J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene
This article was originally published in The Pink Sheet Daily
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
New England Journal of Medicine editorial says that if Phase II results for Celgene’s oral antisense candidate mongersen (GED-0301) are confirmed, the drug’s durable effect “would be unprecedented and would represent a first step toward curing the disease.”
The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.